Raymond James Reiterates an 'Outperform' on Celgene (CELG); Revlimid Growth Continues

Raymond James reiterates an 'Outperform' on Celgene (NASDAQ: CELG) price target of $81.00.

Analyst, Christopher Raymond, said, "Like the chances for Revlimid revenue to bounce back in Q112 following consecutive misses the previous two quarters, based on new Hem/Onc survey feedback showing upward US momentum remains intact. In that we have sensed some degree of investor anxiety about slowing Revlimid growth prior to an EU front-line/maintenance label, we think this feedback should go a long way towards putting such concerns to rest."

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $79.10 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amazon.com (AMZN) PT Raised to $215 at UBS
• JPMorgan Upgrades Unilever Indonesia Tbk (UNVR:IJ) (UNLRF) to Neutral
• Goldman Sachs Downgrades Parade Technologies Ltd. (4966:TT) to Sell